SCNI (Scinai Immunotherapeutics) 6-1 Month Momentum % : -2.75% (As of Mar. 29, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-03-29), Scinai Immunotherapeutics's 6-1 Month Momentum % is -2.75%.

The industry rank for Scinai Immunotherapeutics's 6-1 Month Momentum % or its related term are showing as below:

SCNI's 6-1 Month Momentum % is ranked better than
58.87% of 1483 companies
in the Biotechnology industry
Industry Median: -11.04 vs SCNI: -2.75

Competitive Comparison of Scinai Immunotherapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Scinai Immunotherapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scinai Immunotherapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's 6-1 Month Momentum % falls into.

Save Embed

;

Save Embed

;

Scinai Immunotherapeutics (NAS:SCNI) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinai Immunotherapeutics (NAS:SCNI) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Scinai Immunotherapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinai Immunotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

2F5:Germany

Address

Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR

Website

https://www.biondvax.com

Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Executives

Samuel J Moed	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain	director, other: Chairman	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Chief Financial Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin	director	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv	director	STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster	director	11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia	officer: Chief Scientist	6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman	director	21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman	director, officer: Chief Executive Officer	269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark	officer: Chief Operating Officer	27 HAILANOT, HERZLIYA L3 4631214
George Lowell	director	33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green	director	354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6